Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors

Journal of Oncology Pharmacy Practice

Volumn 14, Issue 3, 2008, Pages 139-145

  Gibson, Kelli ^a   O'Bryant, Cindy L ^b  

^a ROSE MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Anastrozole; Aromatase inhibitor; Bone mineral density; Breast cancer; Exemestane; Letrozole; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; EXEMESTANE; IBANDRONIC ACID; LETROZOLE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER STAGING; CLINICAL PROTOCOL; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; BREAST TUMOR; METABOLIC BONE DISEASE; MIDDLE AGED; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; OSTEOPOROSIS; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 58249084749     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208091866     Document Type: Article

References (15)

1. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK eds. SEER cancer statistics review, 1975-2004, National Cancer Institute, Bethesda, MD.
2. Brunner LC, Eshilian-Oates L., Kuo TY Hip fractures in adults. Am Fam Physician 2003; 67: 537-42.
3. Baum M., Buzdar AU, Cuzick J. et al. Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 2002; 359: 2131-9.
4. Goss PE, Ingle JN, Martino S. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-802.
5. Boccardo F., Rubagotti A., Amoroso D. et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian Cooperative Study. J Clin Oncol 2001; 19: 4209-15.
6. Coombes RC, Hall E., Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-92.
7. Michaud LB Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer. Am J Health-Syst Pharm 2005; 62: 266-73.
8. Winer EP, Hudis C., Burstein HJ et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-29.
9. Invasive Breast Cancer. Practice Guidelines in Oncology - v.2. 2006. National Comprehensive Cancer Network, Inc. 2005.
10. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A comparison study to NCIC CTG MA.17. J Clin Oncol 2006; 24: 3629-35.
11. Eastell R., Hannon RA, Cuzick J. et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trail. J Bone Miner Res 2006; 21: 1215-23.
12. Mincey BA, Duh MS, Thomas SK et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006; 7: 127-32.
13. Hillner BE, Ingle JN, Chlebowski RT et al. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health in women with breast cancer. J Clin Oncol 2003; 21: 4042-57.
14. Gnant MF, Mlineritsch B., Luschin-Ebengreuth G. et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian breast and colorectal cancer study group. J Clin Oncol 2007; 25: 820-28.
15. Brufsky A., Harker GW, Beck T. et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25: 829-36.